CGEN.TA

Compugen Ltd. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of innovative therapeutic candidates across Israel, the United States, and Europe. The company's primary focus is immuno-oncology, with a robust pipeline of investigational treatments. Key assets in their immuno-oncology portfolio include: COM701, an anti-PVRIG antibody, currently in Phase I clinical trials for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, also in Phase I, being evaluated as a monotherapy in patients with advanced malignancies. Bapotulimab, an antibody designed to target ILDR2, which is undergoing Phase I clinical study for solid tumors. AZD2936, a novel bispecific antibody that targets both TIGIT and PD-1, advancing through Phase I/II clinical studies in patients with advanced or metastatic non-small cell lung cancer. Beyond these clinical-stage programs, Compugen is also pursuing early-stage immuno-oncology research, with a particular emphasis on myeloid targets. The company maintains significant strategic alliances, including: A collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against Compugen's proprietary immune checkpoint regulators. A partnership with Bristol-Myers Squibb to assess the safety and tolerability of COM701 when combined with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in advanced solid tumor patients. An engagement with Johns Hopkins School of Medicine to explore novel T cell and myeloid checkpoint targets. A licensing agreement with AstraZeneca for the development of bispecific and multispecific immuno-oncology antibody products. A research collaboration with Johns Hopkins University focusing on myeloid research. Compugen Ltd. was founded in 1993 and is headquartered in Holon, Israel.